Cat. #160880

MLL-AF9-miR-139 knock out cell line

Name: MLL-AF9-miR-139 knock out cell line
SKU: 160880
Availability: InStock

Cat. #: 160880

Availability: 10-12 weeks

Organism: Mouse

Tissue: Bone Marrow

Disease: Cancer

Model: Cancer Model

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Enquire or request a quote

Contributor

Inventor: Stefan Erkeland

Institute: Erasmus Medical Center

Tool Details

Target Details

Handling

References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

Name: MLL-AF9-miR-139 knock out cell line
Alternate name: miR-139
Cancer type: Blood cancer
Cancers detailed: Acute Myeloid Leukaemia (AML)
Research fields: Cancer
Parental cell: Lineage negative bone marrow cells isolated from miR139 KO mice
Organism: Mouse
Tissue: Bone Marrow
Donor: Lineage negative bone marrow cells were isolated from miR139 KO mice and transduced with MLL-AF9.
Disease: Cancer
Growth properties: Enhanced Proliferation
Model: Cancer Model
Conditional: No
Description: MIR-139 is a critical tumor surpressor in AML
Production details: Lineage negative bone marrow cells were isolated from miR139 KO mice and transduced with MLL-AF9.
Recommended controls: MIR139 WT, MLL-AF9 cells

Target Details

Target: MIR139

Handling

Growth medium: As published in Stavast, C.J., van Zuijen, I., Karkoulia, E. et al. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis. Leukemia 36, 687ÄË?Â?Â700 (2022). https://doi.org/10.1038/s41375-021-01461-5

References

Stavast et al. 2022. Leukemia. 36(3):687-700. PMID: 34741119.